GIANNELLA, Mario
 Distribuzione geografica
Continente #
NA - Nord America 11.360
EU - Europa 5.046
AS - Asia 4.302
SA - Sud America 459
AF - Africa 157
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 36
Totale 21.406
Nazione #
US - Stati Uniti d'America 10.973
CN - Cina 1.886
SG - Singapore 1.188
RU - Federazione Russa 1.159
DE - Germania 896
IT - Italia 804
BR - Brasile 389
VN - Vietnam 345
UA - Ucraina 342
CA - Canada 329
GB - Regno Unito 327
SE - Svezia 321
HK - Hong Kong 306
FI - Finlandia 301
PL - Polonia 283
FR - Francia 278
TR - Turchia 137
ZA - Sudafrica 117
KR - Corea 114
IE - Irlanda 81
IN - India 79
CZ - Repubblica Ceca 63
BD - Bangladesh 58
JP - Giappone 49
AU - Australia 44
BE - Belgio 42
NL - Olanda 38
MX - Messico 37
EU - Europa 35
AR - Argentina 27
IR - Iran 24
ES - Italia 23
IQ - Iraq 21
LT - Lituania 15
EC - Ecuador 14
EG - Egitto 14
HR - Croazia 12
PK - Pakistan 12
RO - Romania 12
ID - Indonesia 10
AT - Austria 8
RS - Serbia 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
MA - Marocco 7
VE - Venezuela 7
CO - Colombia 6
KE - Kenya 6
TW - Taiwan 6
AL - Albania 5
CH - Svizzera 5
DZ - Algeria 5
JO - Giordania 5
PE - Perù 5
PH - Filippine 5
AZ - Azerbaigian 4
CL - Cile 4
GR - Grecia 4
HN - Honduras 4
HU - Ungheria 4
IL - Israele 4
JM - Giamaica 4
NP - Nepal 4
PA - Panama 4
PY - Paraguay 4
BY - Bielorussia 3
GE - Georgia 3
KG - Kirghizistan 3
KH - Cambogia 3
MY - Malesia 3
TH - Thailandia 3
UZ - Uzbekistan 3
BG - Bulgaria 2
BO - Bolivia 2
CR - Costa Rica 2
LB - Libano 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AO - Angola 1
BH - Bahrain 1
BZ - Belize 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GH - Ghana 1
GT - Guatemala 1
IS - Islanda 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LK - Sri Lanka 1
MK - Macedonia 1
MN - Mongolia 1
MT - Malta 1
MU - Mauritius 1
Totale 21.395
Città #
Dallas 985
Jacksonville 836
Woodbridge 820
Ashburn 814
Chandler 671
Fairfield 652
Singapore 649
Ann Arbor 534
San Jose 462
Wilmington 432
Houston 413
Beijing 328
Boardman 326
Hong Kong 300
Nanjing 281
Seattle 271
Toronto 209
Cambridge 196
Dearborn 191
Los Angeles 190
The Dalles 161
Warsaw 158
New York 152
Helsinki 147
Düsseldorf 140
San Mateo 133
Council Bluffs 131
Ho Chi Minh City 125
Kraków 121
Seoul 109
Columbus 107
Lawrence 107
Tongling 107
Johannesburg 106
Princeton 106
Camerino 100
Istanbul 99
Nanchang 97
Lauterbourg 96
Munich 89
Buffalo 81
Dublin 81
Moscow 77
Ogden 77
Hanoi 69
Kunming 68
London 68
Shanghai 68
Lachine 67
Shenyang 66
Orem 58
Santa Clara 58
Tianjin 51
Brno 47
São Paulo 47
Guangzhou 46
Jiaxing 46
Turku 45
Hebei 44
Venezia 44
Milan 43
Brussels 42
Changsha 39
Chicago 39
Tokyo 36
Jinan 34
Hangzhou 31
San Diego 31
Denver 30
Chennai 29
Redwood City 29
Philadelphia 28
Montreal 27
Washington 27
Zhengzhou 26
Poplar 25
Wuhan 25
Falls Church 24
Frankfurt am Main 24
Venice 24
Boston 22
Hefei 21
Stockholm 21
Sydney 21
Brooklyn 20
Taizhou 20
Da Nang 19
Leawood 19
Manchester 18
Phoenix 18
Amsterdam 17
Ningbo 17
Nürnberg 17
Orange 17
Ankara 16
Atlanta 16
Mexico City 16
Monmouth Junction 16
Redondo Beach 16
Fuzhou 15
Totale 14.134
Nome #
1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3 Muscarinic Receptor Antagonists 623
1,4-DIOXANE NUCLEUS AS A SUITABLE SCAFFOLD FOR NOVEL D2-LIKE RECEPTOR LIGANDS 622
1,4-Dioxane ring as a promising template of novel 5-HT1A full agonists 560
1'-Benzyl-3,4-dihydrospiro[2H-1-benzothiopyran-2,4'-piperidine] (Spipethiane), a potent and highly selective sigma1 lingand 555
Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation 339
The Versatile 2-Substituted Imidazoline Nucleus as a Structural Motif of Ligands Directed to the Serotonin 5-HT1A Receptor 332
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 323
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 299
Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction 290
33rd camerino-Cyprus Symposium - Receptor Chemistry: Reality and Vision 268
Novel ligands rationally designed for characterizing I2-imidazoline binding sites nature and functions 268
2-(2-Phenylcyclopropyl)imidazolines: Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors 259
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement. 250
The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1A receptor over α1-adrenoceptor and D2-like receptor subtypes 247
Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation 243
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease 241
Multitarget 1,4-Dioxane Compounds Combining Favorable D2-like and 5-HT1A Receptor Interactions with Potential for the Treatment of Parkinson's Disease or Schizophrenia 241
alpha(2)-Adrenoreceptors profile modulation. 2. Biphenyline analogues as tools for selective activation of the alpha2C-subtype 237
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 236
Identification of 2-aminopyrimidine derivatives as inhibitors of the canonical Wnt signaling pathway 227
Discovery of Highly Selective Imidazoline Receptor Ligands 224
33rd Camerino-Cyprus Symposium - Receptor Chemistry: Reality and Vision 219
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 218
Imidazoline binding sites (IBS) profile modulation: Key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues 218
Structure-activity relationships in 1,4-benzodioxan-related compounds. Investigation on the role of the dehydrodioxane ring on alpha1-adrenoreceptor blocking activity 218
77-LH-28-1 as a model for the rational design of selective dopamine D4 receptor ligands 218
Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors 218
Novel 1,4-dioxane derivatives as NMDA receptor channel blockers 217
Role of the NMDA Receptor in the Antitumor Activity of Chiral 1,4-Dioxane Ligands in MCF-7 and SKBR3 Breast Cancer Cells 216
3-Phenyl analogues of 2-[[[2-(2,6-Dimethoxyphenoxyethyllamino]methyl]-1,4-benzodioxan (WB 4101) as highly selective alpha1-adrenoreceptor antagonists1 212
Structure−Activity Relationships in 1,4-Benzodioxan-Related Compounds. 11.1 Reversed Enantioselectivity of 1,4-Dioxane Derivatives in α1‑Adrenergic and 5‑HT1A Receptor Binding Sites Recognition 212
Novel Highly Potent and Selective σ1 Receptor Antagonists Related to Spipethiane 211
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 209
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 209
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 208
Rapid novel divergent synthesis and muscarinic agonist profile of all four optical isomers of N,N,N-trimethyl(6-methyl-1,4-dioxan-2-yl)methanaminium iodide. 207
Synthesis and muscarinic properties of (1S*,3R*,5R*)-trimethyl(1-methyl-6-oxabicyclo[3.1.0]hex-3-yl)methyl ammonium iodide 206
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 204
Homoazanicotine: A structure-affinity study for nicotinic acetylcholine (nACh) receptor binding 202
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 201
Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit an antidepressant-like effect 200
Alpha(2)-Adrenoreceptors Profile Modulation. 3. (R)-(+)-m-Nitrobiphenyline, a New Efficient and alpha(2C)-Subtype Selective Agonist. 198
BIOLOGICAL PROFILE AND BIOAVAILABILITY OF IMIDAZOLINE COMPOUNDS AFFECT THEIR MODULATORY ACTIVITY ON MORPHINE TOLERANCE 198
Use of frozen sections for the pharmacological characterization of compounds active on neurotransmitter receptors 197
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation 197
4WD to Travel Inside the 5-HT1A Receptor World 197
28th Camerino-Cyprus-Noordwijkerhout Symposium - Trekking through Receptor Chemistry 195
Might Adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine? 193
Potent muscarinic antagonists bearing 1,4-dioxane scaffold 192
Enantioselective interactions to improve adrenergic α2C-agonism/α2A-antagonism 191
Solution-phase synthesis of ICG-001, a beta-turn peptidomimetic molecule inhibitor of beta-catenin-Tcf-mediated transcription 190
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 189
Allyphenyline analogues potentially useful in the management of chronic pain and opioid addiction. 188
Chain-lengthened and imidazoline analogues of nicotine 187
Muscarinic Thioligands with Cyclopentane Nucleus 187
Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity 186
The Camerino symposium series (1978-2013): a privileged observatory of receptorology development 186
Novel Potent 5-HT1a Agonists Selective over alpha1-Adrenoceptor Subtypes 186
NOVEL BIVALENT LIGANDS OF XANOMELINE AND 77-LH-28-1 AS POTENTIAL M1 MUSCARINIC AGONISTS 183
DOPAMINE D2, D3, AND D4 RECEPTOR AFFINITIES OF 77-LH-28-1 AND ITS ANALOGUES 181
Synthesis, Absolute Configuration, and Biological Profile of the Enantiomers of trans-[2-(2,6-Dimethoxypheoxy)ethyl] [(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (Mephendioxan), a Potent Competitive alpha 1A-Adrenoreceptor Antagonist 180
Dioxane and Oxathiane Nuclei: Suitable Substructures for Muscarinic Agonists 180
Age-related Changes in the Density of Muscarinic Cholinergic M1 and M2 Receptor Subtypes in Pyramidal Neurons or the rat Hippocampus 179
Ligand binding to I2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models 179
Fruitful Adrenergic alpha(2C)-Agonism/alpha(2A)-Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence 178
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4 chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation 178
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 176
Agonists and antagonists targeting the different alpha(2)-adrenoceptor subtypes 175
Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity 173
alpha(2)-adrenoreceptors profile modulation. 4. From antagonist, to agonist behavior 172
Pharmacophore development and 3D-QSAR study of I1 imidazoline binding site ligands 171
The 2-substituted imidazoline ring linked to an aromatic moiety by a biatomic bridge: a bioversatile scaffold 171
Rational design of novel I1-imidazoline receptor agonists 170
MORPHINE TOLERANCE MODULATION INDUCED BY alpha2-ADRENERGIC OR/AND I2 IMIDAZOLINE BINDING SITES LIGANDS 169
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9.From 1,4-benzodioxan to 1,4-dioxane ring as a promising template of novel alpha(1D)-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents. 169
Might adrenergic α2C-agonist/α2A-antagonist become a novel therapeutic multitarget tool for morphine chronic treatment of pain? 168
Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands 166
From benzodioxane to 1,4-dioxane scaffold in the design of 5-HT1A serotoninergic full agonists from α1-adrenergic antagonists 164
I recettori adrenergici 163
Imidazoline nucleus as a biologically versatile scaffold 162
Byciclic dioxolanes as potential antimuscarinic agents 161
Rational design of new alpha(2)-adrenoreceptor agonists 157
Synthesis and muscarinic activity of some muscarone analogs 156
Structure- Activity Relationships in 1,4-Benzodioxan-related Compounds. 4. Effect of aryl and alkyl Substituents at Position 3 on α-adrenoreceptor blocking activity 156
NOVEL IMIDAZOLINE MOLECULES INSPIRED BY THE PHARMACOLOGICAL PROFILE OF AGMATINE AS POTENTIAL TOOLS IN MANAGING OPIOID ADDICTION 153
Hybrid molecules from xanomeline and 77-LH-28-1 as potential novel M1 muscarinic agonists 151
Design and synthesis of novel imidazoline derivatives potentially targeting dopamine receptors 143
Structure-Activity Relationships in 1,4-Benzodioxan-Related Compounds. 6. Role of the Dioxane Unit on Selectivity for Alpha1-Adrenoreceptor Subtypes 143
Binding of Tracizolines to the Imidazoline Receptor. Role of Lipophilicity in Quantitative Structure-Activity Relationship Models. 143
Molecular determinants in the binding of novel 1,4-benzodioxan-related α1D-adrenergic receptor antagonists: a computational study 141
Aminopyrimidines as inhibitors of the Wnt signalling pathway 140
Enantiomers of 6,6-diphenyl-1,4-dioxane derivatives to highlight stereochemical requirements for selective alpha1D-AR and 5- HT1A receptor recognition 136
Copresence of 1,4-dioxane and quinuclidine nuclei in the design of novel muscarinic antagonists 135
Structure-activity relationships in 1,4-benzodioxan-related compounds. 10. Novel alpha1-adrenoreceptor antagonists related to openphendioxan: synthesis, biological evaluation, and alpha1d computational study 131
Might the observed alpha2A-adrenoreceptor agonism or antagonism of allyphenyline analogues be ascribed to different molecular conformations? 129
Novel muscarinic antagonists designed on the 1,4-dioxane scaffold 129
Structure- Activity Relationships in 1,4-Benzodioxan-related Compounds. 5. Effects of Modification of the side chain on alpha-adrenoreceptor blocking Activity 126
Novel α1-adrenoreceptor antagonists related to openphendioxan: biological evaluation and α1d computational study 121
Coupling of I-1 Imidazoline Receptors to the cAMP Pathway: Studies with a Highly Selective Ligand, Benazoline 119
ANTIDEPRESSANT-LIKE ACTIVITY OF NOVEL IMIDAZOLINE LIGANDS DIRECTED TO THE SEROTONIN 5-HT1A RECEPTOR 119
Totale 20.960
Categoria #
all - tutte 79.821
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.821


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021194 0 0 0 0 0 0 0 0 0 0 0 194
2021/20221.135 94 281 14 78 83 61 29 77 86 125 76 131
2022/20231.704 200 67 71 269 183 227 10 105 313 97 108 54
2023/20241.105 167 63 74 33 46 97 45 17 113 40 25 385
2024/20253.507 142 80 283 168 88 193 427 825 296 225 245 535
2025/20265.694 323 396 1.144 748 605 440 808 323 278 299 259 71
Totale 21.652